An Oral JAK Inhibitor for a Long-Haul Trucker With a Cardiovascular Risk Factor
An oral JAK inhibitor would solve a real cold-chain problem for a patient who lives out of a truck cab for weeks at a time. It would also put him squarely inside the demographic the drug's own boxed warning was written for.
Walter K. has driven long-haul freight routes for twenty-nine years, most of them alone, and describes his low back pain the way a lot of truckers describe their bodies generally — as something you manage, not something you mention, until three weeks of morning stiffness that wouldn't loosen even after four hours behind the wheel finally sent him to a clinic near a weigh station instead of home. Imaging and an HLA-B27-positive result confirmed ankylosing spondylitis; an adequate NSAID trial he squeezed in around two delivery cycles left his BASDAI at 6.5, active enough to move to a first biologic. He is also, by his own accounting, a pack-a-day smoker of thirty years and carries a blood pressure that's run in the 150s systolic on his last three visits, untreated because he "doesn't have time for another pill on top of everything."
His stated preference, once the conversation turned to actual drugs, was immediate and specific: something oral. He spends three to four weeks at a stretch living out of a sleeper cab with no reliable refrigeration and irregular access to a clinic for injection training or supply pickup, and he's watched a fellow driver's injectable biologic go bad after a refrigerator failure on a cross-country haul. A JAK inhibitor would solve that problem cleanly — and would also place him inside the exact population the drug's own safety data was generated on. ORAL Surveillance enrolled rheumatoid arthritis patients aged 50 or older with at least one additional cardiovascular risk factor — and the protocol's own list of qualifying risk factors names current smoking, high blood pressure and an HDL below 40 mg/dL, three boxes Walter ticks by himself at 54. The trial failed to demonstrate non-inferiority to a TNF inhibitor on its two co-primary endpoints, major adverse cardiovascular events and malignancy excluding non-melanoma skin cancer; the thrombosis and mortality signals came from separate analyses rather than that non-inferiority test, a distinction worth keeping straight even though it doesn't soften the conclusion. It is the finding behind the class-wide boxed warning now carried by every JAK inhibitor used in inflammatory arthritis, axSpA included.
A fasting lipid panel drawn at this visit, his first in over three years, added one more data point to the same picture: LDL 168 mg/dL, HDL 34 mg/dL, both abnormal enough on their own to independently justify treatment regardless of which arthritis drug he ultimately starts. Nothing in his exam suggests his axial disease itself is unusually severe — reduced but not absent spinal mobility, no peripheral joint involvement — which is part of why the actual disagreement in the room is almost entirely about the cardiovascular numbers rather than the rheumatologic ones.
An oral pill for a patient who lives on the road
A JAK inhibitor is a real, guideline-recommended option here, and it solves a problem the injectable alternatives genuinely don't: he lives in a truck cab for a month at a stretch with no dependable refrigeration. An injectable biologic that spoils on route isn't safer just because its label doesn't carry a boxed warning — it's a drug he can't actually take. Upadacitinib is oral, room-temperature stable, and removes the cold-chain problem entirely.
I take the logistics problem seriously, and I don't think it's a small consideration. But ORAL Surveillance enrolled patients aged 50 or older with at least one additional cardiovascular risk factor and found tofacitinib failed to show non-inferiority to a TNF inhibitor on both of its co-primary endpoints — major adverse cardiovascular events and malignancy. He's 54, a current 30-pack-year smoker, with untreated hypertension running in the 150s. That's not an adjacent population to worry a little about — that's the trial's own enrollment criteria, describing him specifically.
Convenience is a real value, but it doesn't get to outrank a randomized safety finding in the exact demographic sitting in front of us. If we're going to accept that trade, we should at least be honest that it's a trade against the trial's own population match, not a marginal extrapolation.
There's a version of this that doesn't force a choice between his logistics and his heart. His hypertension and smoking are both independently modifiable, and neither has been treated yet. Starting antihypertensive therapy and a cessation program now, while starting adalimumab — which has a well-established safety record in this exact age group and doesn't carry this specific boxed warning — gets him effective, deliverable disease control today. If his cardiovascular risk factors are genuinely addressed over the next year, a JAK inhibitor becomes a much more defensible second-line option later, on his own improved numbers rather than his current ones.
Agreed: adalimumab started with an on-the-road self-injection and cold-storage plan built around his actual route schedule; lisinopril and a structured smoking-cessation referral started the same visit; blood pressure and lipid panel to be rechecked at 8 weeks.
Not agreed: how much weight the logistics argument should carry if his cardiovascular risk factors genuinely improve. The rheumatologist would revisit a JAK inhibitor as soon as his hypertension is controlled and he has a documented quit attempt underway; the cardiologist wants at least six months of sustained risk-factor control, not just an initiated program, before treating a boxed cardiovascular warning as meaningfully offset.